Suppr超能文献

日本精神分裂症患者对抗精神病药物制剂的满意度调查

Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan.

作者信息

Hatano Masakazu, Takeuchi Ippei, Yamashita Kanade, Morita Aoi, Tozawa Kaori, Sakakibara Takashi, Hajitsu Genta, Hanya Manako, Yamada Shigeki, Iwata Nakao, Kamei Hiroyuki

机构信息

Departments of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.

Departments of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan.

出版信息

Clin Psychopharmacol Neurosci. 2021 Nov 30;19(4):610-617. doi: 10.9758/cpn.2021.19.4.610.

Abstract

OBJECTIVE

To identify factors affecting adherence to medication, a subjective questionnaire survey was administered to schizophrenia patients regarding the prescribed antipsychotic formulations.

METHODS

We evaluated the patients' satisfaction and dissatisfaction with prescribed antipsychotic formulations, and patients answered the Drug Attitude Inventory-10 Questionnaire (DAI-10). Inclusion criteria for patients are as follows: age between 20 and 75 years and taking antipsychotic agents containing the same ingredients and formulations, for at least 1 month.

RESULTS

In total, 301 patients answered the questionnaire survey. Tablets were found to be the most commonly used antipsychotic formulations among schizophrenia patients (n = 174, 57.8%), followed by long-acting injections (LAIs, n = 93, 30.9%). No significant differences in the formulation satisfaction level and DAI-10 scores were observed between all formulations. Formulations, except for LAI, were selected by physicians in more than half of the patients. Patients who answered "Decided by consultation with physicians" had significantly higher satisfaction levels and DAI-10 scores compared to those who answered "Decided by physicians" (4.11 ± 0.77 vs. 3.80 ± 1.00, = 0.0073 and 6.20 ± 3.51 vs. 4.39 ± 4.56, < 0.001, respectively). Satisfaction levels moderately correlated with DAI-10 scores (r = 0.48, < 0.001).

CONCLUSION

No formulation had a high satisfaction level in all patients, and it is important to be reflect the patients' individual preferences in pharmacotherapy. Shared decision-making in the selection of the formulations is seen to be useful for improving medication adherence.

摘要

目的

为确定影响药物治疗依从性的因素,针对精神分裂症患者就所开具的抗精神病药物剂型开展了一项主观问卷调查。

方法

我们评估了患者对所开具抗精神病药物剂型的满意与不满意情况,患者回答了药物态度量表10问卷(DAI - 10)。患者的纳入标准如下:年龄在20至75岁之间,服用含相同成分和剂型的抗精神病药物至少1个月。

结果

共有301名患者回答了问卷调查。片剂是精神分裂症患者中最常用的抗精神病药物剂型(n = 174,57.8%),其次是长效注射剂(LAIs,n = 93,30.9%)。所有剂型之间在剂型满意度水平和DAI - 10评分上未观察到显著差异。除长效注射剂外,超过半数患者的剂型是由医生选择的。回答“由与医生协商决定”的患者相比回答“由医生决定”的患者,满意度水平和DAI - 10评分显著更高(分别为4.11±0.77对3.80±1.00,P = 0.0073;6.20±3.51对4.39±4.56,P < 0.001)。满意度水平与DAI - 10评分呈中度相关(r = 0.48,P < 0.001)。

结论

没有一种剂型在所有患者中都具有高满意度,在药物治疗中考虑患者的个人偏好很重要。在剂型选择中采用共同决策被认为有助于提高药物治疗依从性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验